Winfried Stephan Wels - Nanotechnology

Author Information

Winfried Stephan Wels is a distinguished researcher affiliated with the Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy in Frankfurt, Germany. His work primarily focuses on the field of cancer immunotherapy, with a particular emphasis on the development and application of chimeric antigen receptor (CAR) technologies and natural killer (NK) cells for targeting various types of tumors.

Research Contributions

Winfried Stephan Wels has made significant contributions to the field of cancer immunotherapy. His research includes the engineering of NK cells and CAR T cells to target tumor cells more effectively. In 2021, he published several impactful papers on topics such as the functional distinction of NK cell populations, the retargeting of NK-92 cells against high-risk rhabdomyosarcomas, and the enhancement of antitumor activity through bispecific antibodies. His work also addresses the challenges of tumor antigen escape and the safe genomic integration of CAR-NK cells using non-viral methods. His research has a profound impact on advancing cell-based therapies for cancer treatment.

Aliases

Winfried Stephan Wels is known by several aliases including Winfried S. Wels, W Wels, W. Wels, W S Wels, W. S. Wels, Winfried Wels, and Winfried S Wels.

Publication and Citation Metrics

Metric	Value
Total Citation Count	11107
h-index	56
Total Paper Count	214

Publications:

Innate-like NKp30+CD8+ T cells armed with TCR/CAR target tumor heterogeneity

DOI: 10.1080/2162402X.2021.1973783

Year: 2021

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity

DOI: 10.3389/fimmu.2021.798087

Year: 2021

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

DOI: 10.3390/cancers13061443

Year: 2021

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity

DOI: 10.1136/jitc-2021-002980

Year: 2021

Expression of Potential Targets for Cell-Based Therapies on Melanoma Cells

DOI: 10.3390/life11040269

Year: 2021

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting

DOI: 10.1136/jitc-2020-001334

Year: 2021

Non-Viral Sleeping Beauty Transposon Engineered CD19-CAR-NK Cells Show a Safe Genomic Integration Profile and High Antileukemic Efficiency

DOI: 10.1182/blood-2021-153999

Year: 2021

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

DOI: 10.1172/JCI152477

Year: 2021

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

DOI: 10.1038/s41467-020-17175-8

Year: 2020

Live cell imaging of lytic granule motility in anti-ErbB2 CAR NK cells and FcR NK cells plus Herceptin towards ErbB2+ breast cancer cells

DOI: 10.1016/j.jcyt.2020.04.068

Year: 2020

What are the Key Technologies Used?

What are the Applications of Nanosensors in Biosensing?

What are Nanoparticle Enhanced Drugs?

How Does Epibone Utilize Nanotechnology?

What are Photoactivatable Fluorescent Proteins?

Can Nanotechnology Enhance Material Science?

How Do Policymakers and Regulatory Bodies Contribute?

Why Are Ferromagnetic Nanomaterials Important?

How Does Photoluminescence Work?

What are the potential risks of not being proactive?

Partnered Content Networks

Relevant Topics